Cashu | Summary | NCNA

HomeWatchlistNewsSignalsPicks

DJI

+0.77%

SPX

+0.83%

IXIC

+1.02%

FTSE

-0.21%

N225

+0.06%

AXJO

+0.08%

HomeWatchlistNewsSignalsPicks

Stocks

0.00 (0.00%)

0.000

USD

At close at --,----

Cashu is the #1 way to stay ahead of the markets, know why your favourite stocks are moving and access valuation signals that smash the market.

Company

About Us
Careers
Blog
News

Help & Support

Help Center
Contact Us
Pro Support

Legal

Privacy Policy
Terms of Use

Instagram YouTube

© 2024 Cashu PTY LTD.

Overview

Loading chart...

Join our newsletter to keep up to date with us!

Key Stats

Market Cap

211.46K

Dividend Yield

0.00%

P/E Ratio

-0.01

EPS

-10.58

Revenue

-

Avg. Volume

351.93K

About

What does NCNA do?

NuCana PLC is a UK-based biopharmaceutical company focused on cancer treatments using ProTide technology, with candidates NUC-3373 and NUC-7738 currently in Phase I/II clinical trials. The company's pipeline also includes Acelari, a ProTide transformation of gemcitabine.

Sector

💻 Health Care

IPO

CEO

Employees

Headquarters

United Kingdom

Website

http://www.nucana.com

Recently from Cashu

Request for Content to Summarize Regarding NuCana plc

NuCana plc: Request for Content Submission to Summarize

Please provide the content you would like summarized.

Stocks

Health Care

ncna

NuCana plc

NCNA

-0.00 (-5.13%)

0.0536

USD

At close at Jul 03, 20:43 UTC